JP2022531696A - 特定のｖｍａｔ２阻害剤を投与するための方法 - Google Patents

特定のｖｍａｔ２阻害剤を投与するための方法 Download PDF

Info

Publication number
JP2022531696A
JP2022531696A JP2021565932A JP2021565932A JP2022531696A JP 2022531696 A JP2022531696 A JP 2022531696A JP 2021565932 A JP2021565932 A JP 2021565932A JP 2021565932 A JP2021565932 A JP 2021565932A JP 2022531696 A JP2022531696 A JP 2022531696A
Authority
JP
Japan
Prior art keywords
patient
parkinson
vmat2 inhibitor
symptoms
signs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021565932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531696A5 (https=
Inventor
ダオ トゥエット タイ－クアルト，
バルバラ ショルツ，
グレース エス． リャン，
エイリー ダブリュー． ロバーツ，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2022531696A publication Critical patent/JP2022531696A/ja
Publication of JP2022531696A5 publication Critical patent/JP2022531696A5/ja
Priority to JP2024187589A priority Critical patent/JP2025013963A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021565932A 2019-05-09 2020-05-08 特定のｖｍａｔ２阻害剤を投与するための方法 Pending JP2022531696A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024187589A JP2025013963A (ja) 2019-05-09 2024-10-24 特定のｖｍａｔ２阻害剤を投与するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845599P 2019-05-09 2019-05-09
US62/845,599 2019-05-09
PCT/US2020/032188 WO2020227672A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187589A Division JP2025013963A (ja) 2019-05-09 2024-10-24 特定のｖｍａｔ２阻害剤を投与するための方法

Publications (2)

Publication Number Publication Date
JP2022531696A true JP2022531696A (ja) 2022-07-08
JP2022531696A5 JP2022531696A5 (https=) 2023-05-15

Family

ID=70919120

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565932A Pending JP2022531696A (ja) 2019-05-09 2020-05-08 特定のｖｍａｔ２阻害剤を投与するための方法
JP2024187589A Pending JP2025013963A (ja) 2019-05-09 2024-10-24 特定のｖｍａｔ２阻害剤を投与するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024187589A Pending JP2025013963A (ja) 2019-05-09 2024-10-24 特定のｖｍａｔ２阻害剤を投与するための方法

Country Status (17)

Country Link
US (2) US20200397779A1 (https=)
EP (1) EP3965764A1 (https=)
JP (2) JP2022531696A (https=)
KR (1) KR20220007105A (https=)
CN (1) CN114340624A (https=)
AU (2) AU2020270145A1 (https=)
BR (1) BR112021020709A2 (https=)
CA (1) CA3136466A1 (https=)
EA (1) EA202193012A1 (https=)
IL (2) IL321020A (https=)
JO (1) JOP20210274A1 (https=)
MA (1) MA55893A (https=)
MX (1) MX2021013132A (https=)
PH (1) PH12021552745A1 (https=)
SG (1) SG11202111465RA (https=)
TW (1) TWI850377B (https=)
WO (1) WO2020227672A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
CA3220946A1 (en) * 2021-06-30 2023-01-05 Angel S. Angelov Valbenazine for use in the add-on treatment of schizophrenia
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法
EP4489754A1 (en) * 2022-03-07 2025-01-15 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
WO2025038959A1 (en) * 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) * 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025188830A1 (en) * 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518499A (ja) * 2015-06-23 2018-07-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952A (en) 1838-09-27 I antoni bengini
US10065A (en) 1853-10-04 Improvement in machines for topping cotton jn the field
NZ725826A (en) * 2014-05-06 2023-05-26 Neurocrine Biosciences Inc Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518499A (ja) * 2015-06-23 2018-07-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN INVESTIG DRUGS, vol. 24, no. 6, JPN6024016212, 25 March 2015 (2015-03-25), pages 737 - 742, ISSN: 0005519369 *
PRESWICK PHARMACEUTICALS; ET AL: "XENAZINE (TETRABENAZINE) TABLETS", [ONLINE], JPN5022008328, 2008, pages 6 - 32, ISSN: 0005313085 *

Also Published As

Publication number Publication date
WO2020227672A1 (en) 2020-11-12
TW202108138A (zh) 2021-03-01
JOP20210274A1 (ar) 2023-01-30
US20200397779A1 (en) 2020-12-24
MA55893A (fr) 2022-03-16
PH12021552745A1 (en) 2022-07-11
AU2025256123A1 (en) 2025-11-13
EA202193012A1 (ru) 2022-03-02
IL321020A (en) 2025-07-01
MX2021013132A (es) 2021-11-25
US20220040169A1 (en) 2022-02-10
CN114340624A (zh) 2022-04-12
JP2025013963A (ja) 2025-01-28
BR112021020709A2 (pt) 2021-12-14
CA3136466A1 (en) 2020-11-12
KR20220007105A (ko) 2022-01-18
AU2020270145A1 (en) 2021-12-23
EP3965764A1 (en) 2022-03-16
IL287902A (en) 2022-01-01
SG11202111465RA (en) 2021-11-29
TWI850377B (zh) 2024-08-01

Similar Documents

Publication Publication Date Title
JP2022531696A (ja) 特定のｖｍａｔ２阻害剤を投与するための方法
JP7603662B2 (ja) 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法
US11026931B2 (en) Methods for the administration of certain VMAT2 inhibitors
TW202345830A (zh) 特定vmat2抑制劑的投予方法
JP2024514874A (ja) ある特定のｖｍａｔ２阻害剤の投与のための方法
HK40068979B (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
HK40068979A (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
WO2025038959A1 (en) Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) Valbenazine for use in the treatment of huntington's chorea
WO2025096823A1 (en) Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204